Compare iShares MSCI ACWI ETF (ACWI) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Incyte Corporation — how do they compare? iShares MSCI ACWI ETF trades at $155.9, while Incyte Corporation trades at $117.33 (market cap $23.10B). The key difference: Incyte Corporation is trading nearer its 52-week high, iShares MSCI ACWI ETF nearer its low. Which is the better fit depends on your goals.
| ACWI | INCY | |
|---|---|---|
52-Week High | $159.97 | $118.05 |
52-Week Low | $128.32 | $67.38 |
Market Cap | — | $23.10B |
Sector | — | Health |
Enterprise Value | — | $19.12B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
